Research and Publications

Dr. Chovatiya’s research focus includes the intersection of cutaneous immunology and inflammatory disease. He has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, and improving care across diverse skin types. His research efforts include publications in the areas of:

-Clinical trials

-Patient-reported outcomes

-Health services research

-Epidemiology

-Implementation science

-Health and Social Disparities

-Translational therapy

-Immunology

-And much more

2026

1. Bunick CG, Chovatiya R, Torres T, Eyerich K, Talia J, Altman K, Oza M, Truong B, Calimlim B, Issa NT. Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies. Poster presentation. European Academy of Dermatology and Venereology Annual Meeting, Vienna, Austria. September 30-October 3, 2026.
2. Irvine AD, Silverberg JI, Bunick CG, Vleugels RA, Chovatiya R, Lima H, Torres T, Eyerich K Imafuku, S Katoh N, Gao X, Calimlim B, Hu X, Yang Y, Dilley D, Levy GF, Goel S, Altmfan K, Pechonkina A. Efficacy and Safety of Upadacitinib Through 188 Weeks in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results. Poster presentation. New Zealand Dermatological Society Inc. Annual Scientific Meeting, Hamilton, New Zealand. August 26, 2026.
3. Ardern-Jones M, Alexis A, AlMurrawi M, Bradley M, Chovatiya R, Flohr C, Irvine A, Staumont-Sallé D, Atwater AR, Ding Y, Konicek B, Pierce E, Qiao M, Yang C, Pau-Charles I, Heath C, Waibel J. Lebrikizumab Demonstrates Significant Efficacy and Stable Long-Lasting Response in Atopic Dermatitis Patients with Skin of Colour. Poster presentation. The British Association of Dermatology Annual Meeting, Manchester, UK. June 30-July 2, 2026.
4. Gooderham MJ, Chovatiya R, Weidinger S, Zuotao Z, Okubo Y, Lazariciu I, Koppensteiner H, Chen S, Tsang C. Treatment patterns and efficacy among biologic-naïve and biologic-exposed patients with moderate-to-severe atopic dermatitis: JADE REAL post-hoc analysis. Poster presentation. Maui Derm NP+PA Summer 2026, Colorado Springs, CO. June 24-27, 2026.
5. Chovatiya R, DiRuggiero D, Sardana J, Vinson T. Chronic Hand Eczema treatment burden: Results from a survey of dermatology healthcare professionals. Poster presentation. Maui Derm NP+PA Summer 2026, Colorado Springs, CO. June 24-27, 2026.
6. Armstrong AW, Bunick CG, Chovatiya R, Bissonnette R, Warren RB, Crépy MN, Hussain S, Erhan U, Vinson T, Maslin D, Yu J. Efficacy and safety of delgocitinib cream for moderate to severe Chronic Hand Eczema in adults with Fitzpatrick skin types IV-VI: Post hoc analysis of the DELTA 1 and 2 trials. Poster presentation. Maui Derm NP+PA Summer 2026, Colorado Springs, CO. June 24-27, 2026.
7. Pinto PH, Asadullah K, Chovatiya R, Magnolo N, Napolitano M, Woo PN, Popovic K, Nawaz H, Li Q, Gooderham MJ. Ruxolitinib Cream Is Efficacious in Adults With Moderate Atopic Dermatitis Regardless of Baseline Disease Severity and Previous Medication History. Poster presentation. Canadian Dermatology Association Annual Meeting, Calgary, Canada. June 24-26, 2025.
8. Chovatiya R, Balu S, Sawad AB, Apol ED, Schneider S, Maslin D, Brignoli L, Le Calvé P, Simpson E. Health-related quality of life in people with Chronic Hand Eczema - results from the CHECK study in the United States. Poster presentation. Revolutionizing Atopic Dermatitis Annual Meeting, Nashville, TN. June 17-19, 2026.
9. Wollenberg A, Chovatiya R, Park CO, Ribero S, Silvestre JF, Hong HC, Seneschal J, Saeki H, Bennike NH, von Eben R, Tindberg AM, Blauvelt A. Tralokinumab provides long-term control of head and neck atopic dermatitis: end-of treatment results from the 5-year open-label ECZTEND study. Poster presentation. Revolutionizing Atopic Dermatitis Annual Meeting, Nashville, TN. June 17-19, 2026.Chovatiya R, Mummert A, Chang S, Levenberg M, Bell G, Watkins M, Scott A. Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis Observed in Electronic Health Records and Administrative Claims in a US-Based Real-World Dermatology Setting: Patient Characteristics and Baseline Disease Severity. Poster presentation. Revolutionizing Atopic Dermatitis Annual Meeting, Nashville, TN. June 17-19, 2026.
10. Geng B, Chovatiya R, Shahriari M, Gomez NN, Ng KJ, Ding Y, Gallo G, Seneschal J. Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis. Poster presentation. European Academy of Allergy and Clinical Immunology Annual Meeting, Istanbul, Turkey. June 12-15, 2026.
11. Chovatiya R, Thaçi D, Gooderham M, Ständer S, Binamer Y, Hong HC, Legat FJ, Calleja LR, Hernández F, Valls-Bancells J, Pierce E, Qiao M, Wolf E, Ng KJ, Metz M. Impact of simultaneous skin clearance and itch relief with lebrikizumab in patients with atopic dermatitis: post-hoc analysis from ADvocate1/2. Poster presentation. European Academy of Allergy and Clinical Immunology Annual Meeting, Istanbul, Turkey. June 12-15, 2026.
12. Chovatiya R, Forman S, Alavi A, van der Zee HH, Miyagawa T, Gooderham M, Pansar I, Rolleri R, Datye A, Zouboulis. Bimekizumab efficacy by disease duration and severity in moderate to severe hidradenitis suppurativa: 3-year phase 3 results from BE HEARD EXT. Poster presentation. The 125th Annual Meeting of the Japanese Dermatological Association, Kyoto, Japan. June 11-14, 2026.
13. Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras-Nart I, Casillas M, Gallo G, Ding Y, Pierce E, Agell H, Vestergaard C. Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Maintains Depth of Response Over 3 Years in Week 16 Responders. Poster presentation. The 125th Annual Meeting of the Japanese Dermatological Association, Kyoto, Japan. June 11-14, 2026.
14. Chovatiya R, Zirwas M, Simpson EL, Gooderham MJ, de Bruin-Weller M, Weidinger S, Biswas P, Chan G, Koppensteiner H. Flexible dosing of abrocitinib in patients with moderate-to-severe atopic dermatitis: Initial results from the Real-World-Simulating Expanded Access Protocol Study, JADE REAL. Poster presentation. Society of Dermatology Physician Associates Annual Summer Dermatology Conference, Denver, CO. June 10-14, 2026.
15. Chovatiya R, Zirwas M, Gooderham MJ, Weidinger S, de Bruin-Weller M, Sinclair R, Ramaker S, Selfridge A, Biswas P, Levenberg M, Encinas G, Koppensteiner H. Efficacy of Abrocitinib Flexible Dose Escalation and Reduction Versus Consistent Dosing in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Real World–Simulating Expanded Access Protocol Study, JADE REAL. Poster presentation. PANP360, Scottsdale, AZ. May 29-31, 2026.
16. Gooderham MJ, Chovatiya R, Weidinger S, Zuotao Z, Okubo Y, Lazariciu I, Koppensteiner H, Tsang C, Chen S. Time to efficacy outcomes among biologic-naive and -exposed patients with moderate-to-severe atopic dermatitis: A post-hoc analysis of JADE REAL. Poster presentation. PANP360, Scottsdale, AZ. May 29-31, 2026.
17. Armstrong AW, Bunick CG, Chovatiya R, Bissonnette R, Warren RB, Crépy MN, Hussain S, Erhan U, Vinson T, Maslin D, Yu J. Efficacy and safety of delgocitinib cream for moderate to severe Chronic Hand Eczema in adults with Fitzpatrick skin types IV-VI: Post hoc analysis of the DELTA 1 and 2 trials. Poster presentation. PANP360, Scottsdale, AZ. May 29-31, 2026.
18. Chovatiya R, DiRuggiero D, Sardana J, Vinson T. Chronic Hand Eczema treatment burden: Results from a survey of dermatology healthcare professionals. Poster presentation. PANP360, Scottsdale, AZ. May 29-31, 2026.
19. Armstrong AW, Bunick CG, Chovatiya R, Bissonnette R, Warren RB, Crépy MN, Hussain S, Erhan U, Vinson T, Maslin D, Yu J. Efficacy and safety of delgocitinib cream for moderate to severe Chronic Hand Eczema in adults with Fitzpatrick skin types IV-VI: Post hoc analysis of the DELTA 1 and 2 trials. Poster presentation. Congress of Clinical Dermatology 2026, Amelia Island, FL. May 28-31, 2026.
20. Chovatiya R, DiRuggiero D, Sardana J, Vinson T. Chronic Hand Eczema treatment burden: Results from a survey of dermatology healthcare professionals. Poster presentation. Congress of Clinical Dermatology 2026, Amelia Island, FL. May 28-31, 2026.
21. Simpson EL, Irvine AD, Gutermuth J, Hong HC, Chovatiya R, Guttman-Yassky E, Fan H, Chan G, Lumpan C, Alderfer J, Koppensteiner H. Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure. Poster presentation. Eastern Allergy Meeting 2026, Palm Beach, FL. May 28-31, 2026.
22. Duarte B, Chovatiya R, Thaçi D, Shi V, Yang B, Talia J, Yamamoto A, Prefontaine D, Punia V, Pechonkina A, Lane M, Calimlim BM, Silverberg JI. Efficacy of Upadacitinib vs Dupilumab Treatment for Moderate to Severe Atopic Dermatitis: Analysis of Time Spent in Response State from the Level Up Study. Poster presentation. Australasian College of Dermatology Annual Meeting, Melbourne, Australia. May 16-18, 2026.
23. Bunick CG, Stein Gold LF, Vleugels RA, Chovatiya R, Cotter DG, Zirwas M, Luna PC, Chu CY, Grada A, Dilley DM, Yue E, Oza M, Pechonkina A, Wegrzyn L, Levy GF, Silverberg JI. Patients with Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer). Poster presentation. Australasian College of Dermatology Annual Meeting, Melbourne, Australia. May 16-18, 2026.
24. Chovatiya R, Domingues E, Lain E, Hong HC, Schlesinger T, Woolery-Lloyd H, Krupa D, Jaworski JC, Seal MS, Hanna D, Burnett P, Stephenson B. Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis and Prior Inadequate Response, Intolerance, and/or Contraindication to Topical Antifungals and/or Topical Corticosteroids. Oral presentation (oral poster). Society of Investigative Dermatology Annual Meeting, Chicago, IL. May 13-16, 2026.
25. Chovatiya R, Alavi A, Shi VY, van der Zee HH, Gooderham M, Miyagawa T, Zouboulis CC, Oh T, Crater C, Tilt N, Sabat R. Bimekizumab Efficacy by Disease Duration and Severity in Moderate to Severe Hidradenitis Suppurativa: 3-year Phase 3 Results from BE HEARD EXT. Poster presentation. SIDeMaST 2026, Rimini, Italy. April 21-24, 2026.
26. Bissonnette R, Buhl T, Grewal P, Guttman-Yassky E, Reguiaï Z, Simpson EL, Worm M, Maslin D, Norlin JM, Thoning H, Chovatiya R. Patient reported outcome measures and symptom improvements across subtypes of Chronic Hand Eczema: outcomes from the Phase 3 DELTA-1 and DELTA-2 trials. Poster presentation. Poster presentation. Real World Dermatology for Residents 2026, Las Vegas, NV. April 16-18, 2026.
27. Armstrong AW, Bernier C, Bissonnette R, Chovatiya R, Magnolo N, Toth DP, Baranowski K, Maslin D, Schneider SKR, Thoning H, Silverberg JI. “Super-response” following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe Chronic Hand Eczema. Poster presentation. Real World Dermatology for Residents 2026, Las Vegas, NV. April 16-18, 2026.
28. Chovatiya R, Kircik L, Binamer Y, Puig L, Torres T, Akmaz B, Dossenbach M, Gallo G, Yang C, Ding Y, Cho YT. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe atopic dermatitis treated with lebrikizumab plus topical corticosteroids versus dupilumab plus topical corticosteroids. Poster presentation. AMCP Annual Meeting, Nashville, TN. April 13-April 16, 2026.
29. Chovatiya R, Soung J, Jaworski JC, Seal MS, Hanna D, Stephenson B. Real-World Insights Into First-Line Use of Topical Roflumilast Cream for Psoriasis. Poster presentation. AMCP Annual Meeting, Nashville, TN. April 13-April 16, 2026.
30. Chovatiya R, Stephenson B, Rasouliyan, L, Strober B. Prevalence and Advanced Systemic Treatment Prescription Patterns for Scalp Psoriasis in the Real-World Dermatology Setting in the United States. Poster presentation. AMCP Annual Meeting, Nashville, TN. April 13-April 16, 2026.
31. Simpson E, Biedermann T, Kircik L, Chovatiya R, Figueras-Nart I, Casillas M, Gallo G, Ding Y, Pierce E, Agell H, Vestergaard C. Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Maintains Depth of Response Over 3 Years in Week 16 Responders. Poster presentation. GLAD FORUM 2026, Utrecht, Netherlands. April 9-10, 2026.
32. Bavaro N, Farishta A, Chen J, Chovatiya R. Real World Efficacy and Safety of the IL-36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
33. Malhotra S, Woo D, Chovatiya R. Unmet Dermatologic Needs and Barriers to Care Among South Asians: A Community-Based U.S. Survey. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
34. Malhotra S, Woo D, Chovatiya R. Psychosocial Barriers to Dermatologic Care Among South Asians: A Community-Based U.S. Survey. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
35. Malhotra S, Woo D, Chovatiya R. The Role of Cultural Norms and Traditional Medicine in Dermatologic Care Among South Asians: A Community-Based U.S. Survey. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
36. Pandey AK, Chovatiya R. Association between seborrheic dermatitis and psoriasis and impact on healthcare utilization: evidence from the National Ambulatory Medical Care Survey. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
37. Mense S, Li C, Hopkins T, Maher S, Chovatiya R. Assessing the Use and Variability of Patient-Reported Outcomes in Seborrheic Dermatitis Clinical Studies: A Systematic Review and Analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
38. Mense S, Li C, Hopkins T, Maher S, Chovatiya R. Assessing the Use and Variability of Clinician-Reported Outcomes in Seborrheic Dermatitis Clinical Studies: A Systematic Review and Analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
39. Mense S, Li C, Hopkins T, Maher S, Chovatiya R. Assessing the Use and Variability of Clinician-Reported Outcomes in Seborrheic Dermatitis Clinical Studies: A Systematic Review and Analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
40. Farishta A, Bavaro N, Chang CH, Chovatiya R. Clinical Efficacy and Skin Barrier Impact of Colloidal Oatmeal in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
41. Woo D, Malhotra S, Chang C, Hung A, Chovatiya R. Prevalence and Bidirectional Association of Vitiligo and Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
42. Woo D, Malhotra S, Chang C, Hung A, Chovatiya R. Prevalence and Bidirectional Association of Hidradenitis Suppurativa (HS) and Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
43. Mense S, Hopkins T, Chovatiya R. Prevalence and Risk of Cardiovascular Comorbidities and Cardiometabolic Factors in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
44. Chang CH, Devine M, Woo D, Hopkins T, Torres, Chovatiya R. Past, Present, and Future of Sodium Hypochlorite in Dermatology: A Scoping Review and Analysis. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
45. Silverberg JI. Bieber T, Chovatiya R, Warren RB, Gooderham M, Gkalpakiotis S, Chaudhry S, Liu Y, Zalevsky J, Rosmarin D. Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026. 
46. Chovatiya R, Gupta MR, Selfridge A, Biswas P, Watkins M. Using Statistical Modeling to Predict Abrocitinib Response After Early Dose Escalation. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
47. Chovatiya R, Weidinger S, Biswas P, Watkins M, Koppensteiner H. Tailoring Treatment With Abrocitinib: Personalized Treatment Approaches Used in the JADE REAL Study. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
48. Bunick CG, Chovatiya R, Torres T, Eyerich K, Talia J, Altman K, Oza M, Truong B, Calimlim B, Issa NT. Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
49. Alexis A, Kindred C, Shahriari M, Chovatiya R, Dawson Z, Zhong J, Seminario-Vidal L, Wollenberg A, Seneschal J, Vestergaard C. Lebrikizumab Rapidly Improves Head, Neck and Face Atopic Dermatitis in Adults and Adolescents with Skin of Color (ADmirable). Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
50. Chovatiya R, Luo S, Zhang Z, Jasper P, Morabito C, Mugundu G. Model-Informed Development of STAR-0310 Supporting Every-3-Month and Every-6-Month Dosing in Atopic Dermatitis. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
51. Chovatiya R, Alavi A, Shi VY, van der Zee HH, Gooderham M, Miyagawa T, Zouboulis CC, Oh T, Crater C, Tilt N, Sabat R. Bimekizumab Efficacy by Disease Duration and Severity in Moderate to Severe Hidradenitis Suppurativa: 3-year Phase 3 Results from BE HEARD EXT. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
52. Chovatiya R, Dillon P, Fielding R, Howell O, Rastrick J, Vanvoorden V, Irvine AD. Unmet needs in atopic dermatitis treated with current biologic therapies: results from an international cross-sectional cohort study. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
53. Pinto PH, Asadullah K, Chovatiya R, Magnolo N, Napolitano M, Woo PN, Popovic K, Nawaz H, Li Q, Gooderham MJ. Ruxolitinib Cream Is Efficacious in Adults With Moderate Atopic Dermatitis Regardless of Baseline Disease Severity and Previous Medication History. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
54. Chovatiya R, Balu S, Sawad AB, Apol ED, Schneider S, Maslin D, Brignoli L, Le Calvé P, Simpson E. Health-related quality of life in people with Chronic Hand Eczema - results from the CHECK study in the United States. Poster presentation. American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
55. Simpson E, Balu S, Sawad AB, Apol ED, Schneider S, Maslin D, Brignoli L, Rault B, Morillo A, Chovatiya R. Patient-perceived factors associated with Chronic Hand Eczema – results from the CHECK study in the United States. Poster presentation (oral poster). American Academy of Dermatology Annual Meeting, Denver, CO. March 27-31, 2026.
56. Bunick CG, Stein Gold LF, Vleugels RA, Chovatiya R, Cotter DG, Zirwas M, Luna PC, Chu CY, Grada A, Dilley DM, Yue E, Oza M, Pechonkina A, Wegrzyn L, Levy GF, Silverberg JI, Karaca R. Patients with Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer). Poster presentation. Dermatolojide Zor Hastalıklar Zirvesi, Istanbul, Turkey. March 13-15, 2026.
57. Simpson E, Balu S, Sawad AB, Apol ED, Schneider S, Maslin D, Le Calvé P, Moussallem A, Chovatiya R. Patient characteristics and comorbidities in moderate to severe chronic hand eczema - Results from the RWEAL-US study. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
58. Chovatiya R, Balu S, Sawad AB, Apol ED, Schneider S, Maslin D, Brignoli L, Rault B, Morillo A, Simpson E. Treatment patterns in chronic hand eczema in the US - Results from the RWEAL-US medical chart review. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
59. Chovatiya R, Balu S, Sawad AB, Apol ED, Schneider S, Maslin D, Brignoli L, Rault B, Simpson E. The multifactorial and heterogenous nature of Chronic Hand Eczema seen in clinical practice in the United States - Results from the RWEAL-US study. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
60. Carrascosa JM, Prajapati VH, Hong HC, Eleftheriadou V, Tsianakas A, Navarini A, Peris K, Song EJ, Chovatiya R, Barbarot S, Popovic K, Nawaz H, Li Q, Wollenberg A. Efficacy and Safety of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis: Results From TRuE-AD4, a Phase 3b, Randomized, Double-Blind, Vehicle-Controlled Study. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
61. Gooderham MJ, Chovatiya R, Weidinger S, Zuotao Z, Okubo Y, Lazariciu I, Koppensteiner H, Tsang C, Chen S. Time-to-efficacy outcomes by observed abrocitinib dosing patterns among patients with moderate-to-severe atopic dermatitis: A post-hoc analysis of JADE REAL. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
62. Simpson EL, Irvine AD, Gutermuth J, Hong HC, Chovatiya R, Guttman-Yassky E, Fan H, Chan G, Lumpan C, Alderfer J, Koppensteiner H. Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
63. Chovatiya R, Poka P, Mitchell B, Heredia EE, Chopade K, Ray D. Using social listening to understand experiences of incretin use among individuals with obesity and psoriasis. Poster presentation. Winter Clinical Miami 2026, Aventura, FL. February 27-March 1, 2026.
64. Kaza U, Geng B, Chovatiya R, Waibel J, Dawson Z, Seminario-Vidal L, Zhang H, Soong W. Lebrikizumab Clears Face Lesions in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis. Poster Presentation. American Academy of Allergy, Asthma, and Immunology Annual Meeting, Philadelphia, PA. February 27-March 2, 2026.
65. Geng B, Boguniewicz M, Mehta V, Fonacier L, Gimeno HA, Dawson Z, Qiao M, Wolf E, Chovatiya R. Advancing Atopic Dermatitis Remission Criteria with Lebrikizumab Results in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis. Poster Presentation. American Academy of Allergy, Asthma, and Immunology Annual Meeting, Philadelphia, PA. February 27-March 2, 2026.
66. Chovatiya R, Florea A, Muthuri S, Clouser M, Kouznetsova M, Ma J, Qian J, Herr F, Bouloc A, Kricorian G, Cordey M, Ehst BD. Real-world Treatment Patterns of Biologics and Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis in the United States. Poster Presentation. American Academy of Allergy, Asthma, and Immunology Annual Meeting, Philadelphia, PA. February 27-March 2, 2026.
67. Carrascosa JM, Prajapati VH, Hong HC, Eleftheriadou V, Tsianakas A, Navarini A, Peris K, Song EJ, Chovatiya R, Barbarot S, Popovic K, Nawaz H, Li Q, Wollenberg A. Efficacy and Safety of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis: Results From TRuE-AD4, a Phase 3b, Randomized, Double-Blind, Vehicle-Controlled Study. Poster presentation. KOPRA 2026, Leipzig, Germany. February 26-28, 2026.
68. Armstrong A, Bewley A, Wollenberg A, Hong HC, von Eyben R, Jonsen E, Maslin D, Langford B, Walker K, Chovatiya R. Matching-Adjusted Indirect Comparison of the Efficacy at week 12 of Delgocitinib and topical PUVA in the treatment of Severe Chronic Hand Eczema. Poster presentation. KOPRA 2026, Leipzig, Germany. February 26-28, 2026.
69. Bissonnette R, Buhl T, Grewal P, Guttman-Yassky E, Reguiaï Z, Simpson EL, Worm M, Maslin D, Norlin JM, Thoning H, Chovatiya R. Patient reported outcome measures and symptom improvements across subtypes of Chronic Hand Eczema: outcomes from the Phase 3 DELTA-1 and DELTA-2 trials. Poster presentation. South Beach Symposium 2026, Miami Beach, FL. February 5-7, 2026.
70. Armstrong AW, Bernier C, Bissonnette R, Chovatiya R, Magnolo N, Toth DP, Baranowski K, Maslin D, Schneider SKR, Thoning H, Silverberg JI. “Super-response” following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe Chronic Hand Eczema. Poster presentation. South Beach Symposium 2026, Miami Beach, FL. February 5-7, 2026.
71. Wollenberg A, Chovatiya R, Park CO, Ribero S, Silvestre JF, Hong HC, Seneschal J, Saeki H, Bennike NH, von Eben R, Tindberg AM, Blauvelt A. Tralokinumab provides long-term control of head and neck atopic dermatitis: end-of treatment results from the 5-year open-label ECZTEND study. Poster presentation. South Beach Symposium 2026, Miami Beach, FL. February 5-7, 2026.
72. Chovatiya R, Treat JR, Rosmarin D, Corren J, Bieber T, Warren RB, Lio P, Gooderham M, Sadick N, Gkalpakiotis S, Reich A, Chaudhry S, Lee Z, Hannaway M, Yu D, Liu Y, Fanton C, Zhang M, Waltz W, Gilbert J, Charoenthongtrakul S, Jue C, Marcondes M, Kotzin B, Tagliaferri M, Zalevsky J, Silverberg JI. Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial. Poster presentation. Maui Derm 2026, Maui, Hawaii. January 25-29, 2026.
73. Shahriari M, Cotter DG, Torres T, Chovatiya R, Lio P, Eyerich K, Grada A, Lane M, Calimlim BM, Armendariz Y, Pechonkina A, Irvine AD. Achieving and Maintaining Optimal Outcomes for Skin Clearance, Itch Relief, and Minimal Disease Activity With Upadacitinib: 188-Week Results From the Measure Up 1 and Measure Up 2 Studies. Poster presentation. Maui Derm 2026, Maui, Hawaii. January 25-29, 2026.
74. Gooderham MJ, Kindred C, Chovatiya R, Asempa O, Bhutani T, Kircik LH, Stein Gold LS, Hong HC, Jaworski JC, Seal MS, Burnett P, Stephenson B. Pattern of Improvement in Scalp Versus Body Psoriasis With Roflumilast Foam 0.3%: An Analysis of the Phase 3 ARRECTOR Trial. Poster presentation. Maui Derm 2026, Maui, Hawaii. January 25-29, 2026.
75. Chovatiya R, Poka P, Mitchell B, Heredia EE, Chopade K, Ray D. Using social listening to understand experiences of incretin use among individuals with obesity and psoriasis. Poster presentation. Maui Derm 2026, Maui, Hawaii. January 25-29, 2026.
76. Chovatiya R, Zirwas M, Gooderham MJ, Weidinger S, de Bruin-Weller M, Sinclair R, Ramaker S, Selfridge A, Biswas P, Levenberg M, Encinas G, Koppensteiner H. Efficacy of Abrocitinib Flexible Dose Escalation and Reduction Versus Consistent Dosing in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Real World–Simulating Expanded Access Protocol Study, JADE REAL. Poster presentation. Maui Derm 2026, Maui, Hawaii. January 25-29, 2026.
77. Carrascosa JM, Prajapati VH, Hong HC, Eleftheriadou V, Tsianakas A, Navarini A, Peris K, Song EJ, Chovatiya R, Barbarot S, Popovic K, Nawaz H, Li Q, Wollenberg A. Efficacy and Safety of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis: Results From TRuE-AD4, a Phase 3b, Randomized, Double-Blind, Vehicle-Controlled Study. Poster presentation. Maui Derm 2026, Maui, Hawaii. January 25-29, 2026.
78. Gooderham MJ, Chovatiya R, Weidinger S, Zuotao Z, Okubo Y, Lazariciu I, Koppensteiner H, Tsang C, Chen S. Time to efficacy outcomes among biologic-naive and -exposed patients with moderate-to-severe atopic dermatitis: A post-hoc analysis of JADE REAL. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
79. Chovatiya R, McCann W, Aldredge L, Gou R, Tran J, Wallem A, Pierce E, Carter LD, Pandya S, Chi-Chang C, Doshi R, Chang HC, Zhou M, Armstrong A. Real World Assessment of Once-a-Month Dosing of Lebrikizumab in Commercial Claims. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
80. Chovatiya R, Irvine AD, Foley P, Del Rosso J, Puig L, Kamata M, Wollenberg A, Hong HC, Chu CY, Binamer Y, Dossenbach M, Gallo G, Akmaz B, Rand K, Estévez-Carrillo A, Gold LS. Using the Durability Index for Indirect Comparative Analysis of Lebrikizumab, Dupilumab, and Tralokinumab Monotherapy in Atopic Dermatitis: Evaluating Induction and Maintenance Outcomes Across Varying Maintenance Adherence Rates. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
81. Carrascosa JM, Prajapati VH, Hong HC, Eleftheriadou V, Tsianakas A, Navarini A, Peris K, Song EJ, Chovatiya R, Barbarot S, Popovic K, Nawaz H, Li Q, Wollenberg A. Efficacy and Safety of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis: Results From TRuE-AD4, a Phase 3b, Randomized, Double-Blind, Vehicle-Controlled Study. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
82. Armstrong AW, Kircik L, Metelitsa A, Warren R, Rodriguez A, Volc S, Issa N, Chovatiya R, von Eyben R, Festini T, Johansen P, Ehst B. Tralokinumab versus dupilumab for the treatment of moderate to severe atopic dermatitis with hand involvement: a matching-adjusted indirect comparison. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
83. Armstrong AW, Bunick CG, Chovatiya R, Bissonnette R, Warren RB, Crépy MN, Hussain S, Erhan U, Vinson T, Maslin D, Yu J. Efficacy and safety of delgocitinib cream for moderate to severe Chronic Hand Eczema in adults with Fitzpatrick skin types IV-VI: Post hoc analysis of the DELTA 1 and 2 trials. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
84. Chovatiya R, Soung J, Jaworski JC, Seal MS, Hanna D, Stephenson B. Real-World Insights Into First-Line Use of Topical Roflumilast Cream for Psoriasis. Poster presentation. Winter Clinical Hawaii 2026, Maui, Hawaii. January 16-21, 2026.
85. Carrascosa JM, Prajapati VH, Hong HC, Eleftheriadou V, Tsianakas A, Navarini A, Peris K, Song EJ, Chovatiya R, Barbarot S, Popovic K, Nawaz H, Li Q, Wollenberg A. Efficacy and Safety of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis: Results From TRuE-AD4, a Phase 3b, Randomized, Double-Blind, Vehicle-Controlled Study. Poster presentation. Maui Derm Caribbean 2026, San Juan, Puerto Rico. January 7-10, 2026.